Search Result

Results for "

brain-permeable

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) 5-HT Receptor (3) AAK1 (1) Acetyl-CoA Carboxylase (1) Adenylate Cyclase (2) Amyloid-β (2) Apoptosis (1) Autophagy (5) Biochemical Assay Reagents (1) Caspase (1) Cholinesterase (ChE) (7) COX (4) Cytochrome P450 (1) DNA/RNA Synthesis (1) Dopamine Receptor (2) EAAT (1) EGFR (2) Endogenous Metabolite (2) FAAH (1) Ferroptosis (1) Fluorescent Dye (1) GlyT (1) GSK-3 (1) HDAC (1) iGluR (4) Isocitrate Dehydrogenase (IDH) (1) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) LRRK2 (1) mAChR (2) MEK (1) Methionine Adenosyltransferase (MAT) (1) mGluR (3) Mixed Lineage Kinase (1) Molecular Glues (1) Monoamine Oxidase (3) nAChR (3) Neurokinin Receptor (4) Neurotensin Receptor (3) NF-κB (1) NOD-like Receptor (NLR) (3) Orexin Receptor (OX Receptor) (2) p38 MAPK (1) PARP (1) PDK-1 (1) PGE synthase (1) Phosphodiesterase (PDE) (1) Pim (1) PKC (1) Potassium Channel (1) Raf (1) Reference Standards (1) RIP kinase (2) Sirtuin (3) STAT (1) Tau Protein (1) TGF-β Receptor (3) Toll-like Receptor (TLR) (1) Transferrin Receptor (2) TRP Channel (2) α-synuclein (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (2) Endocrinology (3) Inflammation/Immunology (13) Metabolic Disease (4) Neurological Disease (55)
Click Chemistry:	Alkynes (2)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100614

AS1517499 Maximum Cited Publications 35 Publications Verification	STAT	Inflammation/Immunology Cancer
AS1517499 is a potent and brain-permeable STAT6 phosphorylation inhibitor with an IC₅₀ of 21 nM.

HY-16691

AK-7 3 Publications Verification	Sirtuin	Neurological Disease
AK-7 is a selective cell- and brain-permeable SIRT2 inhibitor, with an IC₅₀ of 15.5 μM.

HY-149966

PB131	HDAC	Inflammation/Immunology
PB131 is a selective and brain-permeable HDAC6 inhibitor with high binding affinity (IC₅₀: 1.8 nM). PB131 has potent anti-inflammatory activity. PB131 can be used for research of inflammation, especially neuroinflammation .

HY-15262

SRT 2104 15+ Cited Publications	Sirtuin	Neurological Disease Metabolic Disease Cancer
SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD ⁺ dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease .

HY-131036

MAO-IN-M30 dihydrochloride	Monoamine Oxidase	Neurological Disease
MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible MAO-A (IC₅₀=37 nM) and MAO-B (IC₅₀=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease . MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-136094

SRT3657	Sirtuin	Neurological Disease
SRT3657 is a brain-permeable activator of SIRT1, with neuroprotective effect .

HY-124947

PF-4522654	5-HT Receptor	Neurological Disease
PF-4522654 is a potent, selective and brain-permeable 5-HT_2C receptor agonist with an EC₅₀ of 16 nM and a K_i of 8 nM. PF-4522654 shows no measurable functional agonism at no 5-HT_2A and 5-HT_2B receptors. PF-4522654 can be used for the study of stress urinary incontinence (SUI) .

HY-176487

SARM1-IN-6	Toll-like Receptor (TLR)	Neurological Disease
SARM1-IN-6 (Compound 17a) is a brain-permeable SARM1 orthosteric inhibitor with IC₅₀ of 14 nM for NAM and 74 nM for HEK cells .

HY-10814

CP-810123	nAChR	Neurological Disease
CP-810123 is a brain-permeable agonist of α7 nAChR for the research of cognitive impairment associated with psychiatric or neurological disorders such as schizophrenia and Alzheimer's disease .

HY-119095

L-741671	Neurokinin Receptor	Neurological Disease Endocrinology
L-741671 is a selective and brain-permeable antagonist of neurokininl (hNKI) receptor, with Kis of 64 nM, 0.03 nM and 0.7 nM in rat, human and ferret, respectively .

HY-149202

UT-11	PGE synthase	Inflammation/Immunology
UT-11 is a potent and brain-permeable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor with IC₅₀s of 0.10 μM and 2.00 μM for inhibiting PGE₂ production in human (SK-N-AS) and murine (BV2) cells, respectively .

HY-P991380

TXB4	Transferrin Receptor	Neurological Disease
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .

HY-14552

Talnetant 3 Publications Verification SB 223412	Neurokinin Receptor	Neurological Disease Endocrinology
Talnetant (SB 223412) is a selective, competitive, brain-permeable NK3 receptor antagonist with a K_i of 1.4 nM in hNK-3-CHO cells. Talnetant is 100-fold more selective for hNK-3 relative to the hNK-2 receptor and has no affinity for hNK-1. Talnetant can be used in schizophrenia-related studies .

HY-W686216

VK-28	Ferroptosis	Neurological Disease
VK-28, a brain-permeable iron chelator, inhibits both basal and Fe/ascorbate-induced mitochondrial membrane lipid peroxidation, with an IC₅₀ of 12.7 μM. VK-28 exhibits significant neuroprotective effects on ICV-6-OHDA. VK-28 can be used for the research of Parkinson’s disease and other neurodegenerative diseases .

HY-14552A

Talnetant hydrochloride SB 223412 hydrochloride; SB 223412-A	Neurokinin Receptor	Neurological Disease Endocrinology
Talnetant (SB 223412) hydrochloride is a selective, competitive, brain-permeable NK3 receptor antagonist with a K_i of 1.4 nM in hNK-3-CHO cells. Talnetant hydrochloride is 100-fold more selective for hNK-3 relative to the hNK-2 receptor and has no affinity for hNK-1. Talnetant hydrochloride can be used in schizophrenia-related studies .

HY-18679

TC-N 22A	mGluR	Neurological Disease
TC-N 22A is a potent, selective, orally active and brain-permeable mGlu₄ PAM with an EC₅₀ of 9 nM in human mGlu₄-expressing BHK cells. TC-N 22A is less active (EC₅₀>10 μM) in agonist and PAM model at mGlu 1, 2, 3, 5, and 7 receptors. TC-N 22A has the potential for research of CNS disease in vivo .

HY-133011

nAChR agonist 1	nAChR	Neurological Disease
nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC₅₀ of 0.32 µM in a Ca ²⁺ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .

HY-158115

NST-628	Molecular Glues Raf MEK	Cancer
NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .

HY-16936

JH-II-127	LRRK2	Neurological Disease
JH-II-127 is an orally active, highly potent, selective and brain-permeable LRRK2 inhibitor, with IC₅₀s of 6, 2 and 48 nM for wild-type LRRK2 and LRRK2-G2019S and mutant LRRK2-A2016T. JH-II-127 inhibits Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .

HY-172941

VEN-02XX	NOD-like Receptor (NLR)	Neurological Disease
VEN-02XX is an orally active and brain-permeable NLRP3 inhibitor. VEN-02XX inhibits the release of IL-1β and IL-18 (IC₅₀ 0.3 and 0.28 μM, respectively). VEN-02XX restores memory and cognition, inhibits microgliosis, and reduces neuroinflammation and tau pathology in the 5XFAD/Rubicon KO mouse model. VEN-02XX may be used in the study of Alzheimer's disease (AD) .

HY-155088

MK-8768	mGluR	Metabolic Disease
MK-8768 is a highly potent, orally bioavailable and selective class of mGluR2 negative allosteric modulator (IC₅₀ of 9 .6nM) with excellent *brain permeability*.

HY-W156961

LS-75	PARP	Neurological Disease
LS-75 is a PARP-1 inhibitor with blood-brain permeability and IC₅₀ value of 18 μM. LS-75 has neuroprotective activity .

HY-133555

mGluR2 antagonist 1	mGluR	Neurological Disease
mGluR2 antagonist 1 is a highly potent, orally bioavailable and selective class of mGluR2 negative allosteric modulator (IC₅₀ of 9 nM) with excellent brain permeability .

HY-U00046

Apyramide	COX	Inflammation/Immunology
Apyramide is an anti-inflammatory agent (NSAID) and behaves as a proagent of indomethacin (HY-14397). Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2.

HY-10547

OSU-03012 5 Publications Verification AR-12; PDK1 inhibitor AR-12	PDK-1 Autophagy	Cancer
OSU-03012 (AR-12; PDK1 inhibitor AR-12) is a blood-brain permeable PDK-1 inhibitor with an IC₅₀ of 5 μM .

HY-107409

GNE 5729	iGluR	Neurological Disease
GNE 5729 is a brain permeable positive allosteric modulator of NMDAR, with an EC₅₀ of 37 nM for GluN2A, 4.7 and 9.5 μM for GluN2C and GluN2D, respectively.

HY-146101

NMDA receptor antagonist 5	iGluR	Neurological Disease
NMDA receptor antagonist 5 (Compound 10e) is a potent, brain permeable and non-toxic NMDA receptor antagonist. NMDA receptor antagonist 5 can be used for neurological disorder research .

HY-108337

GNE-0723	iGluR	Neurological Disease
GNE-0723 is a brain permeable positive allosteric modulator of NMDAR, with an EC₅₀ of 21 nM for GluN2A, 7.4 and 6.2 μM for GluN2C and GluN2D, respectively .

HY-163465

DTNP	Fluorescent Dye	Neurological Disease
DTNP is a BchE -activated near infrared (NIR) probe with blood-brain permeability. DTNP can be activated by BchE and inhibit its enzyme activity. DTNP can be used in Alzheimer's disease (AD) research .

HY-157132

FAAH-IN-8	FAAH	Neurological Disease
FAAH-IN-8 (compound 11) is a competitive inhibitor of FAAH with an IC₅₀ value of 6.7 nM and a K_i value of 5 nM. FAAH-IN-8 has high *blood-brain* permeability and a significant antioxidant profile with no neurotoxicity .

HY-155079

DZD1516	EGFR	Cancer
DZD1516 is a potent and selective HER2 inhibitor (IC₅₀=0.56 nM) with good blood-brain permeability. DZD1516 exhibits antitumor activity in CNS and subcutaneous xenograft mouse models .

HY-148246

MU1700	TGF-β Receptor	Cancer
MU1700 is an orally active and potent ALK1/2 inhibitor with IC₅₀s of 13 nM and 6 nM, respectively. MU1700 shows cell membrane permeability and high brain permeability .

HY-163656

MAT2A inhibitor 5	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A inhibitor 5(compound 39) is an orally active, selectivity and blood-brain permeability inhibitor of MAT2A with the IC₅₀ of 11 nM. MAT2A inhibitor 5 inhibits tumor cell growth in vivo .

HY-110176

ASP2535	GlyT	Neurological Disease
ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .

HY-133898

Danavorexton TAK-925	Orexin Receptor (OX Receptor)	Others
Danavorexton (TAK-925) is an orexin receptor agonist with brain permeability. Danavorexton induces a physiological pattern of OX2R activation in vitro to wake up sleepy mice and improve sleepiness symptoms .

HY-161377

M4K2306	TGF-β Receptor	Cancer
M4K2306 is a selective inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 7 nM. M4K2306 is blood brain permeable with a brain to plasma ratio of 75.6 .

HY-161116

AD-5584	Acetyl-CoA Carboxylase	Cancer
AD-5584 is an ACSS2 inhibitor with blood-brain permeability. AD-5584 can significantly reduce lipid storage, reduce colony formation, and increase cell death. AD-5584 has antitumor activity .

HY-169107

RIPK1-IN-25	RIP kinase	Neurological Disease
RIPK1-IN-25 (WL8) is a blood-brain permeable RIPK1 inhibitor with EC₅₀ and K_d values are 19.9 and 25 nM, respectively. RIPK1-IN-25 can be used in the study of neurometabolic diseases .

HY-162235

CVN766	Orexin Receptor (OX Receptor)	Cardiovascular Disease
CVN766 is an orally active inhibitor of orexin 1 receptor antagonist with blood-brain permeability with the IC₅₀ values of 8 nM and >10 μM for OX1R and OX2R, respectively. CVN766 can be used for study schizophrenia .

HY-129545

DS-1001b 1 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity .

HY-108920

4-Chlorokynurenine 4-Cl-KYN; AV-101	iGluR	Neurological Disease
4-Chlorokynurenine (4-Cl-KYN) is a prodrug of a NMDA receptor antagonist, 7-Chlorokynurenic acid (HY-100811). 4-Chlorokynurenine has orally active and blood-brain permeability that can be used for the research of depression .

HY-161376

M4K2281	TGF-β Receptor	Cancer
M4K2281 is a selecitve inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 2 nM. M4K2281 exhibits a moderate blood brain permeability with a brain to plasma ratio of 3.7 at 4h .

HY-172101

AChE/MAO-B-IN-7	Cholinesterase (ChE) Monoamine Oxidase Amyloid-β	Neurological Disease
AChE/MAO-B-IN-7 (VAV-8) is a blood-brain permeable dual inhibitor of acetylcholinesterase (AchE) and MAO-B agent. AChE/MAO-B-IN-7 can also inhibit Aβ42 aggregation for use in Alzheimer's disease (AD) research .

HY-153268

Silevertinib BDTX-1535; EGFR-IN-76	EGFR	Cancer
BDTX-1535 (EGFR-IN-76) is an orally available, blood-brain permeable, selective EGFR inhibitor with anti-tumor activity. BDTX-1535 is indicated in a variety of models including non-small cell lung cancer, glioblastoma patient-derived tumors, and intracranial tumors .

HY-158155

CVN293	Potassium Channel NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
CVN293 is a selective and brain permeable potassium ion (K ⁺) channel KCNK13 inhibtor with IC₅₀s of 41 nM and 28 nM for hKCNK13 and mKCNK13, respectively. CVN293 potently inhibits the NLRP3-inflammasome mediated production of the proinflammatory cytokine IL-1β in microglia .

HY-14397S

Indomethacin-d4 Indometacin-d₄	Isotope-Labeled Compounds COX Autophagy	Inflammation/Immunology Cancer
Indomethacin-d₄ is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells . Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-111274

Indomethacin farnesil Indometacin farnesil	COX Autophagy	Inflammation/Immunology
Indomethacin farnesil is an orally active proagent of Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-B1343

Pridinol mesylate	Cholinesterase (ChE)	Neurological Disease
Pridinol mesylate is an orally active, blood-brain permeable, muscarinic acetylcholine receptor (mAChR)-directed muscle relaxant. Pridinol mesylate reduces the conduction of impulses to spinal motor neurons and exerts muscle relaxant activity. Pridinol mesylate inhibits skeletal muscle contractures in diseases of both central and peripheral origin and can be used in research in the field of musculoskeletal diseases .

HY-B1343A

Pridinol	Cholinesterase (ChE)	Neurological Disease
Pridinol is an orally active, blood-brain permeable, muscarinic acetylcholine receptor (mAChR)-directed muscle relaxant. Pridinol reduces the conduction of impulses to spinal motor neurons and exerts muscle relaxant activity. Pridinol inhibits skeletal muscle contractures in diseases of both central and peripheral origin and can be used in research in the field of musculoskeletal diseases .

HY-161992

Nrf2 activator-11	Keap1-Nrf2 Apoptosis	Neurological Disease Inflammation/Immunology
Nrf2 activator-11 (compound M11) is a Nrf2 activator with blood-brain permeability. Nrf2 activator-11 has anti-oxidation, anti-inflammation, anti-ferroptosis and anti-apoptosis. Nrf2 activator-11 can be used to study cerebral  ischemia-reperfusion (CI/R) injury models .

Cat. No.	Product Name	Target	Research Area

HY-P99797

Pabinafusp alfa JR-141	Transferrin Receptor	Neurological Disease
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .

HY-P991380

TXB4	Transferrin Receptor	Neurological Disease
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-155534

17β-HSD10-IN-1	Structural Classification Monophenols Classification of Application Fields Source classification Other Diseases Phenols Endogenous metabolite Disease Research Fields	17β-HSD
17β-HSD10-IN-1 (compound 9) is an orally active inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) with blood-brain permeability. 17β-HSD10-IN-1 doesn't result additional effects for mitochondrial off-targets and cytotoxic or neurotoxic effects .

HY-W018643

Ferulic acid methyl ester Methyl ferulate	Monophenols Classification of Application Fields Neurological Disease Simple Phenylpropanols Stemonaceae Source classification Phenols Phenylpropanoids Plants Disease Research Fields Stemona tuberosa Lour. Cancer	p38 MAPK Autophagy
Ferulic acid methyl ester (Methyl ferulate) is a derivative of ferulic acid, isolated from Stemona tuberosa, with anti-inflammatory and antioxidant properties . Ferulic acid methyl ester is a cell membrane and brain permeable compound, shows free radical scavenging ability, used in the research of neurodegenerative disorders . Ferulic acid methyl ester inhibits COX-2 expression, blocks p-p38 and p-JNK in primary bone marrow derived-macrophages .

HY-113329

Guanidinoethyl sulfonate 2 Publications Verification Taurocyamine	Structural Classification Natural Products Other disease Classification of Application Fields Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Guanidinoethyl sulfonate (Taurocyamine) is an orally available, blood-brain permeable competitive inhibitor of taurine transporters and a competitive antagonist of glycine receptors (GlyR) (IC₅₀=565 μM). Guanidinoethyl sulfonate has both weak agonist and antagonist effects on GABA_A receptors. Guanidinoethyl sulfonate inhibits taurine transmembrane transport and competitively binds to the GlyR ligand binding domain, thereby blocking glycine-mediated chloride influx, and may regulate brain pH to exert neuroprotective effects. Guanidinoethyl sulfonate can be used for neuroprotection studies of ischemic brain injury .

HY-N2909

Aurantiamide	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Source classification Umbelliferae Plants Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray	NF-κB RIP kinase Mixed Lineage Kinase
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-113329R

Guanidinoethyl sulfonate (Standard)	Structural Classification Natural Products Other disease Disease markers Endogenous metabolite	Endogenous Metabolite
Guanidinoethyl sulfonate (Standard) is the analytical standard of Guanidinoethyl sulfonate. This product is intended for research and analytical applications. Guanidinoethyl sulfonate is an orally available, blood-brain permeable competitive inhibitor of taurine transporters and a competitive antagonist of glycine receptors (GlyR) (IC50=565 μM). Guanidinoethyl sulfonate has both weak agonist and antagonist effects on GABAA receptors. Guanidinoethyl sulfonate inhibits taurine transmembrane transport and competitively binds to the GlyR ligand binding domain, thereby blocking glycine-mediated chloride influx, and may regulate brain pH to exert neuroprotective effects. Guanidinoethyl sulfonate can be used for neuroprotection studies of ischemic brain injury .

Cat. No.	Product Name	Chemical Structure

HY-14397S1

Indomethacin-d4 Methyl Ester
Indomethacin-d₄ Methyl Ester is the deuterium labeled Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells . Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-14397S

Indomethacin-d4
Indomethacin-d₄ is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells . Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-B1343AS

Pridinol-d5

Pridinol-d₅ is deuterium labeled Pridinol (HY-B1343A) . Pridinol is an orally active, blood-brain permeable, muscarinic acetylcholine receptor (mAChR)-directed muscle relaxant. Pridinol reduces the conduction of impulses to spinal motor neurons and exerts muscle relaxant activity. Pridinol inhibits skeletal muscle contractures in diseases of both central and peripheral origin and can be used in research in the field of musculoskeletal diseases .

Cat. No.	Product Name		Classification

HY-131036

MAO-IN-M30 dihydrochloride		Alkynes
MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible MAO-A (IC₅₀=37 nM) and MAO-B (IC₅₀=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease . MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks